MiST

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 1, 2018 → Oct 24, 2026

Cited window

Jun 29, 2018 → Sep 14, 2026

Retrieved

Oct 31, 2026

Title

Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma

Also known as

MiST3

Registry

NCT03654833

Study IDs

0627

Sponsor

University of Leicester

Collaborators

British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline

Design

Phase 2 · Interventional, non randomized, parallel

Status

Completed

Enrollment

186 actual

Registered

2018-08-31

Start

2019-01-28 actual

Primary completion

2023-02-21 actual

Primary endpoint

Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –141 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of all HCP opinion, and source totals cannot be interpreted as numbers of independent clinicians.
• –Some relevant discussion of access-dependent sequencing, biomarker-guided treatment choice and interpretations of CONFIRM is not fully represented. Other potentially relevant passages were not examined in detail.
• –The October 2023 comparison of genomic and immune-context findings, sampling timing and explanation of T-cell recruitment is incompletely represented. The April 2024 account of treatment choices after first-line immunotherapy is also incomplete. These gaps limit interpretation of the host-biomarker rationale and the relapsed-treatment sequence.
• –Discussion that used unfamiliar spellings or did not name the trial may be absent. One recording had limited transcript confirmation.
• –Several passages cannot be assigned to a named speaker. Conflicting names in some recordings leave identities unresolved; programme participation alone does not resolve ownership of the words.
• –Many views come from people described in the sources as presenting, authoring or participating in MiST. Those descriptions do not make their opinions independent validation or establish consensus.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Early single-arm activity, historical or cross-trial comparisons and exploratory biological associations do not establish incremental benefit, treatment equivalence or a validated selection rule.
• –A speaker’s MiST5 conclusion conflates 12-week and best-response disease control. Informal descriptions of MiST4’s partner drug or checkpoint class also differ from its protocol; each has been preserved as an attributed statement rather than silently corrected.
• –Statements about treatment standards, access, future trial starts and anticipated presentations belong to their original time and jurisdiction. Dates do not establish a change of mind, and intervention-specific regulatory labeling is not comprehensively established here.
• –Not yet captured in this edition: a view on precision-medicine development and synthetic-lethal treatment approaches for relapsed mesothelioma.
• –Not yet captured in this edition: a question about biomarkers guiding treatment selection in relapsed mesothelioma.
• –Not yet captured in this edition: a view on access-dependent sequencing of chemotherapy and immunotherapy in mesothelioma.
• –Not yet captured in this edition: a view on genomic versus immune response biomarkers, pretreatment sensitivity and uncertainty about T-cell recruitment.
• –Not yet captured in this edition: a view on second-line treatment options for previously treated mesothelioma.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "MiST" (NCT03654833), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "mist-03654833". If you cannot make requests, read https://www.erudio.com/reports/mist-nct03654833.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03654833", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03654833 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/mist-nct03654833.json
curl https://www.erudio.com/reports/mist-nct03654833.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "mist-03654833" })